This Article Full Text Full Text (PDF) All Versions of this Article: 93/6/2084    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wémeau, J. L. Articles by Ladsous, M. Search for Related Content PubMed PubMed Citation Articles by Wémeau, J. L. Articles by Ladsous, M. Related Collections Thyroid

Beneficial Effects of Propylthiouracil plus L-Thyroxine Treatment in a Patient with a Mutation in MCT8

Clinique Endocrinologique Marc Linquette (J.L.W., M.P., E.P.-L., M.L.), Laboratoire de Médecine Nucléaire (M.d’H.), and Unité de Gastro-entérologie et Nutrition Pédiatrique (F.G.), Centre Hospitalier Universitaire, 59 037 Lille, France; and Department of Internal Medicine (J. J., T.J.V.), Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: J. L. Wémeau, Clinique Endocrinologique, 6 rue du Pr Laguesse, CHRU, 59 037 Lille Cedex, France. E-mail: jl-wemeau{at}chru-lille.fr.

Context: Mutations of the monocarboxylate transporter 8 (MCT8) gene determine a distinct X-linked phenotype of severe psychomotor retardation and consistently elevated T₃ levels. Lack of MCT8 transport of T₃ in neurons could explain the neurological phenotype.

Objective: Our objective was to determine whether the high T₃ levels could also contribute to some critical features observed in these patients.

Results: A 16-yr-old boy with severe psychomotor retardation and hypotonia was hospitalized for malnutrition (body weight = 25 kg) and delayed puberty. He had tachycardia (104 beats/min), high SHBG level (261 nmol/liter), and elevated serum free T₃ (FT₃) level (11.3 pmol/liter), without FT₄ and TSH abnormalities. A missense mutation of the MCT8 gene was present. Oral overfeeding was unsuccessful. The therapeutic effect of propylthiouracil (PTU) and then PTU plus levothyroxine (LT₄) was tested. After PTU (200 mg/d), serum FT₄ was undetectable, FT₃ was reduced (3.1 pmol/liter) with high TSH levels (50.1 mU/liter). Serum SHBG levels were reduced (72 nmol/liter). While PTU prescription was continued, high LT₄ doses (100 µg/d) were needed to normalize serum TSH levels (3.18 mU/liter). At that time, serum FT₄ was normal (16.4 pmol/liter), and FT₃ was slightly high (6.6 pmol/liter). Tachycardia was abated (84 beats/min), weight gain was 3 kg in 1 yr, and SHBG was 102 nmol/liter.

Conclusions: 1) When thyroid hormone production was reduced by PTU, high doses of LT₄ (3.7 µg/kg·d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone. 2) High T₃ levels might exhibit some deleterious effects on adipose, hepatic, and cardiac levels. 3) PTU plus LT₄ could be an effective therapy to reduce general adverse features, unfortunately without benefit on the psychomotor retardation.

This article has been cited by other articles:

				L. M. Roberts, K. Woodford, M. Zhou, D. S. Black, J. E. Haggerty, E. H. Tate, K. K. Grindstaff, W. Mengesha, C. Raman, and N. Zerangue Expression of the Thyroid Hormone Transporters Monocarboxylate Transporter-8 (SLC16A2) and Organic Ion Transporter-14 (SLCO1C1) at the Blood-Brain Barrier Endocrinology, December 1, 2008; 149(12): 6251 - 6261. [Abstract] [Full Text] [PDF]